keyword
MENU ▼
Read by QxMD icon Read
search

Prostate pet

keyword
https://www.readbyqxmd.com/read/28103574/68ga-psma-11-pet-ct-for-prostate-cancer-staging-and-risk-stratification-in-chinese-patients
#1
Shiming Zang, Guoqiang Shao, Can Cui, Tian-Nv Li, Yue Huang, Xiaochen Yao, Qiu Fan, Zejun Chen, Jin Du, Ruipeng Jia, Hongbin Sun, Zichun Hua, Jun Tang, Feng Wang
We evaluated the clinical utility of 68Ga-PSMA-11 PET/CT for staging and risk stratification of treatment-naïve prostate cancer (PCa) and metastatic castrate-resistant prostate cancer (mCRPC). Twenty-two consecutive patients with treatment-naïve PCa and 18 with mCRPC were enrolled. 68Ga-PSMA-11 PET/CT and magnetic resonance imaging (MRI) were performed for the evaluation of primary prostatic lesions, and bone scans were used for evaluation bone metastasis. Among the 40 patients, 37 (92.5% [22 treatment-naïve PCa, 15 mCRPC]) showed PSMA-avid lesions on 68Ga-PSMA-11 images...
January 17, 2017: Oncotarget
https://www.readbyqxmd.com/read/28102507/-44-sc-psma-617-for-radiotheragnostics-in-tandem-with-177-lu-psma-617-preclinical-investigations-in-comparison-with-68-ga-psma-11-and-68-ga-psma-617
#2
Christoph A Umbricht, Martina Benešová, Raffaella M Schmid, Andreas Türler, Roger Schibli, Nicholas P van der Meulen, Cristina Müller
BACKGROUND: The targeting of the prostate-specific membrane antigen (PSMA) is of particular interest for radiotheragnostic purposes of prostate cancer. Radiolabeled PSMA-617, a 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA)-functionalized PSMA ligand, revealed favorable kinetics with high tumor uptake, enabling its successful application for PET imaging ((68)Ga) and radionuclide therapy ((177)Lu) in the clinics. In this study, PSMA-617 was labeled with cyclotron-produced (44)Sc (T 1/2 = 4...
December 2017: EJNMMI Research
https://www.readbyqxmd.com/read/28097325/imaging-locally-advanced-recurrent-and-metastatic-prostate-cancer-a-review
#3
Maria L Lindenberg, Baris Turkbey, Esther Mena, Peter L Choyke
Importance: Prostate cancer is the second leading cause of cancer deaths in US men. The course of prostate cancer is highly variable, and timely and accurate detection of clinically significant cancer is critical in positively affecting outcomes. Observations: Molecular imaging methods and magnetic resonance imaging (MRI) are the most promising new developments for prostate tumor visualization. While the benefits of MRI are many, positron emission tomography (PET) radiotracers are still available only as research tools...
January 12, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28074210/diagnostic-value-of-additional-68-ga-psma-pet-before-223-ra-dichloride-therapy-in-patients-with-metastatic-prostate-carcinoma
#4
Axel Bräuer, Kambiz Rahbar, Julia Konnert, Martin Bögemann, Lars Stegger
PURPOSE: Medical imaging plays an important role in selecting patients with metastatic castration-resistant prostate cancer for (223)Ra-dichloride therapy of bone metastases. The purpose of this study was to investigate whether (68)Ga-PSMA-PET has incremental value over conventional imaging for selecting patients suitable for (223)Ra-dichloride therapy. METHODS: In 27 consecutive patients referred for (223)Ra-dichloride therapy additional (68)Ga-PSMA-PET/CT was performed and tracer distribution was evaluated systematically with respect to the detection of visceral metastases and bone metastases with inadequate uptake on bone scintigraphy...
January 11, 2017: Nuklearmedizin. Nuclear Medicine
https://www.readbyqxmd.com/read/28072616/gastrointestinal-stromal-tumor-showing-intense-tracer-uptake-on-psma-pet-ct
#5
Benjamin Noto, Matthias Weckesser, Boris Buerke, Michaela Pixberg, Nemanja Avramovic
A 70-year-old man with suspected prostate cancer was referred for Ga-PSMA-HBED-CC PET/CT (short PSMA PET/CT) for staging of tumor extent. Apart from vivid tracer uptake in the prostate gland and osseous metastasis, PSMA PET/CT revealed a large soft tissue mass with calcifications in the left upper abdomen showing intense tracer uptake. Histologic examination revealed the mass to be a gastrointestinal stromal tumor.
January 9, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28063603/prostate-specific-membrane-antigen-targeted-ligand-positron-emission-tomography-computed-tomography-and-immunohistochemical-findings-in-a-patient-with-synchronous-metastatic-penile-and-prostate-cancer
#6
Michael Froehner, Friederike Kuithan, Klaus Zöphel, Ulrike Heberling, Michael Laniado, Manfred P Wirth
A 68-year-old man presented with synchronous metastatic penile and prostate cancer. 68Ga-labeled prostate-specific membrane antigen-targeted ligand positron emission tomography/computed tomography (PSMA-PET/CT) revealed tracer uptake in inguinal, pelvic, and retroperitoneal metastases. Lymph node biopsies and immunohistochemical staining revealed that both cancers involved the lymph nodes and expressed PSMA. In the deposits of penile squamous cell carcinoma, PSMA expression was seen in tumor vessels and may explain the PSMA-PET/CT positivity of inguinal nodes involved in squamous cell carcinoma...
January 4, 2017: Urology
https://www.readbyqxmd.com/read/28062595/the-clinical-impact-of-additional-late-pet-ct-imaging-with-68ga-psma-11-hbed-cc-in-the-diagnosis-of-prostate-cancer
#7
Ali Afshar-Oromieh, Lars Peter Sattler, Walter Mier, Boris Hadaschik, Jürgen Debus, Tim Holland-Letz, Klaus Kopka, Uwe Haberkorn
PURPOSE: While Positron Emission Tomography/Computed Tomography (PET/CT) with (68)Ga-PSMA-11 in the diagnosis of prostate cancer (PCa) is routinely performed at 1h post injection (p.i.), later scans may be beneficial since most lesions present with higher uptake and contrast. This evaluation aimed to investigate the clinical impact of additional late (68)Ga-PSMA-11-PET/CT. METHODS: Between 2011 and 2016, 112 patients with PCa who received early (at 1h p.i.) and late (at 3h p...
January 6, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28060330/hyperpolarized-13c-metabolic-magnetic-resonance-spectroscopy-and-imaging
#8
Eugen Kubala, Kim A Muñoz-Álvarez, Geoffrey Topping, Christian Hundshammer, Benedikt Feuerecker, Pedro A Gómez, Giorgio Pariani, Franz Schilling, Steffen J Glaser, Rolf F Schulte, Marion I Menzel, Markus Schwaiger
In the past decades, new methods for tumor staging, restaging, treatment response monitoring, and recurrence detection of a variety of cancers have emerged in conjunction with the state-of-the-art positron emission tomography with (18)F-fluorodeoxyglucose ([(18)F]-FDG PET). (13)C magnetic resonance spectroscopic imaging ((13)CMRSI) is a minimally invasive imaging method that enables the monitoring of metabolism in vivo and in real time. As with any other method based on (13)C nuclear magnetic resonance (NMR), it faces the challenge of low thermal polarization and a subsequent low signal-to-noise ratio due to the relatively low gyromagnetic ratio of (13)C and its low natural abundance in biological samples...
December 30, 2016: Journal of Visualized Experiments: JoVE
https://www.readbyqxmd.com/read/28048586/th-ab-206-00-challenges-and-opportunities-for-nuclear-medicine-theranostics
#9
Osama Mawlawi
In the past few decades, the field of nuclear medicine has made long strides with the continued advancement of related sciences and engineering and the availability of diagnostic and therapeutic radionuclides. Leveraging these advancements while combining the advantages of therapeutic and diagnostic radionuclides into one radiopharmaceutical has also created a new subfield "theranostics" in nuclear medicine that has the potential to further propel the field into the future. This session is composed of two talks; one focused on the physics principles of theranostics from properties of beta and alpha emitting radionuclides to dosimetric models and quantification; while the second describes preclinical and clinical applications of theranostics and discusses the challenges and opportunities of bringing them to the clinic...
June 2016: Medical Physics
https://www.readbyqxmd.com/read/28048576/we-h-207a-04-impact-of-lesion-location-on-the-repeatability-of-18f-naf-pet-ct
#10
C Lin, T Perk, S Harmon, S Perlman, G Liu, R Jeraj
PURPOSE: Quantifying the repeatability of imaging biomarkers is critical for assessing therapeutic response. While (18) F-NaF PET/CT has shown to be a repeatable imaging method, research has not shown which factors may influence its repeatability. The purpose of this study was to evaluate whether the location of the lesion impacts the repeatability of quantitative (18) F-NaF PET-derived SUV metrics. METHODS: Metastatic castrate-resistant prostate cancer patients with multiple bone lesions received whole-body test-retest NaF PET/CT scans...
June 2016: Medical Physics
https://www.readbyqxmd.com/read/28047906/su-c-202-01-incorporating-time-dependent-hypoxia-in-imrt-planning
#11
A Roy, O Nohadani
PURPOSE: To incorporate uncertainties in oxygenation of tumor cells into radiation therapy planning via robust optimization. The model is demonstrated using a clinical prostate cancer case. METHODS: The tumor oxygenation levels are determined based on pre- and mid-treatment PET scans. To account for oxygenation changes, we use a radio-sensitivity factor for the effective dose necessary to treat hypoxic cells. Due to the unpredictable nature of re-oxygenation of hypoxic cells, the radio-sensitivity factor and its change is modeled to reside in a time-dependent uncertainty set...
June 2016: Medical Physics
https://www.readbyqxmd.com/read/28047654/mo-ab-bra-05-18f-naf-pet-ct-imaging-biomarkers-in-metastatic-prostate-cancer
#12
S Harmon, T Perk, C Lin, J Eickhoff, P Choyke, W Dahut, A Apolo, J Humm, S Larson, M J Morris, S Perlman, G Liu, R Jeraj
PURPOSE: Clinical use of (18) F-Sodium Fluoride (NaF) PET/CT in metastatic settings often lacks technology to quantitatively measure full disease dynamics due to high tumor burden. This study assesses radiomics-based extraction of NaF PET/CT measures, including global metrics of overall burden and local metrics of disease heterogeneity, in metastatic prostate cancer for correlation to clinical outcomes. METHODS: Fifty-six metastatic Castrate-Resistant Prostate Cancer (mCRPC) patients had NaF PET/CT scans performed at baseline and three cycles into chemotherapy (N=16) or androgen-receptor (AR) inhibitors (N=39)...
June 2016: Medical Physics
https://www.readbyqxmd.com/read/28047394/su-f-j-06-optimized-patient-inclusion-for-naf-pet-response-based-biopsies
#13
A Roth, S Harmon, T Perk, R Jeraj
PURPOSE: A method to guide mid-treatment biopsies using quantitative [F-18]NaF PET/CT response is being investigated in a clinical trial. This study aims to develop methodology to identify patients amenable to mid-treatment biopsy based on pre-treatment imaging characteristics. METHODS: 35 metastatic prostate cancer patients had NaF PET/CT scans taken prior to the start of treatment and 9-12 weeks into treatment. For mid-treatment biopsy targeting, lesions must be at least 1...
June 2016: Medical Physics
https://www.readbyqxmd.com/read/28047393/su-f-r-28-correction-of-fch-pet-bladder-uptake-using-virtual-sinograms-and-investigation-of-its-impact-on-the-quantification-of-prostate-textural-characteristics
#14
S Laberge, J Beauregard, L Archambault
PURPOSE: Textural biomarkers as a tool for quantifying intratumoral heterogeneity hold great promise for diagnosis and early assessment of treatment response in prostate cancer. However, spill-in counts from the bladder uptake are suspected to have an impact on the textural measurements of the prostate volume. This work proposes a correction method for the FCh-PET bladder uptake and investigates its impact on intraprostatic textural properties. METHODS: Two patients with PC received pre-treatment dynamic FCh-PET scans reconstructed at four time points (interval: 2 min), for which prostate and bladder contours were obtained...
June 2016: Medical Physics
https://www.readbyqxmd.com/read/28047036/we-fg-202-05-quantification-of-bone-flare-on-f-18-naf-pet-ct-in-metastatic-prostate-cancer
#15
A Weisman, S Harmon, T Perk, M Scarpelli, G Liu, R Jeraj
PURPOSE: Bone flare has been observed on Tc-99m bone scans during early assessment in metastatic Castration-Resistant Prostate Cancer (mCRPC) patients receiving select androgen-signaling pathway (AR) targeted treatments, including CYP17-inhibitor Abiraterone. This study investigates the appearance and potential clinical impact of bone flare in mCRPC patients receiving CYP17-inhibitors using (18) F-NaF PET/CT. METHODS: Twenty-three mCRPC patients being treated with CYP17-inhibitors received NaF PET/CT scans at baseline, week 6, and week 12 of treatment...
June 2016: Medical Physics
https://www.readbyqxmd.com/read/28047028/th-ab-206-01-advances-in-radionuclide-therapy-from-radioiodine-to-nanoparticles
#16
J Humm
In the past few decades, the field of nuclear medicine has made long strides with the continued advancement of related sciences and engineering and the availability of diagnostic and therapeutic radionuclides. Leveraging these advancements while combining the advantages of therapeutic and diagnostic radionuclides into one radiopharmaceutical has also created a new subfield "theranostics" in nuclear medicine that has the potential to further propel the field into the future. This session is composed of two talks; one focused on the physics principles of theranostics from properties of beta and alpha emitting radionuclides to dosimetric models and quantification; while the second describes preclinical and clinical applications of theranostics and discusses the challenges and opportunities of bringing them to the clinic...
June 2016: Medical Physics
https://www.readbyqxmd.com/read/28047011/we-h-207a-05-spatial-co-localization-of-f-18-naf-vs-f-18-fdg-defined-disease-volumes
#17
P Ferjancic, S Harmon, S Chen, U Simoncic, R Jeraj
PURPOSE: Both [F-18]NaF and [F-18]FDG show promise for quantitative PET/CT assessment in metastatic prostate cancer to bone. Broad agreement between the tracers has been shown but voxel-wise correspondence has not been explored in depth. This study evaluates the spatial co-localization of [F-18]NaF PET and [F-18]FDG PET in bone lesions. METHODS: Seventy-three lesion contours were identified in six patients receiving dynamic NaF PET/CT and FDG PET/CT scans two hours apart using identical fields-of-view...
June 2016: Medical Physics
https://www.readbyqxmd.com/read/28046998/su-f-j-101-stereotactic-body-radiation-therapy-planning-for-primary-prostate-cancer-with-selective-intraprostatic-boost-determined-by-18f-choline-pet-ct
#18
L Wu, H Wang, E Hirata, S Kwee, Y Kuang
PURPOSE: To investigate the utility of (18) F-choline positron emission tomography (PET) scans guidance for SBRT dose painting in patients with prostate cancer and its impact on tumor control probability (TCP) and normal tissue complication probability (NTCP). METHODS: Twenty seven patients with localized prostate cancer who had (18) F-choline PET/CT scan prior to treatment were included. A pair of nested intraprostatic dominant lesion (IDL) contours (IDLsuv60% and IDLsuv70% ) were generated for each patient based on 60% and 70% of maximum prostate uptake on the (18) F-choline PET images...
June 2016: Medical Physics
https://www.readbyqxmd.com/read/28046372/th-ab-206-02-nuclear-medicine-theronostics-wave-of-the-future-pre-clinical-and-clinical-opportunities
#19
E Delpassand
In the past few decades, the field of nuclear medicine has made long strides with the continued advancement of related sciences and engineering and the availability of diagnostic and therapeutic radionuclides. Leveraging these advancements while combining the advantages of therapeutic and diagnostic radionuclides into one radiopharmaceutical has also created a new subfield "theranostics" in nuclear medicine that has the potential to further propel the field into the future. This session is composed of two talks; one focused on the physics principles of theranostics from properties of beta and alpha emitting radionuclides to dosimetric models and quantification; while the second describes preclinical and clinical applications of theranostics and discusses the challenges and opportunities of bringing them to the clinic...
June 2016: Medical Physics
https://www.readbyqxmd.com/read/28045734/prostate-specific-membrane-antigen-pet-ct-uptake-in-lymph-nodes-with-active-sarcoidosis
#20
André Henrique Dias, Mikkel Holm Vendelbo, Kirsten Bouchelouche
We describe 2 cases of Ga-PSMA PET/CT in prostate cancer patients. Both cases demonstrated symmetrical bilateral involvement of mediastinal and hilar lymph nodes besides findings in relation with prostatic disease. In both cases, endobronchial ultrasound-guided biopsy showed that the involvement of the thoracic lymph nodes was caused by nonnecrotic granulomas compatible with sarcoidosis. The cases demonstrated that increased Ga-PSMA uptake can be seen in lymph nodes with active sarcoidosis, with images mimicking those well known from FDG PET/CT...
December 30, 2016: Clinical Nuclear Medicine
keyword
keyword
11205
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"